TYME Technologies Inc

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
TYME Technologies Inc. is an emerging biotech company that won "Best Public Company Presentation" at BioNJ 2019 BioPartnering Conference, and was featured by NJEDA at BIO2019.

Our goal is to transform certain advanced and difficult-to-treat cancers into diseases that are either curable or that can be managed as chronic conditions so that cancer patients can lead longer and better-quality live. At TYME, we are applying the latest advances in the field of cancer metabolism to develop novel cancer metabolism-based therapies (CMBTs) that target the mechanisms of disease at their source, and thereby create significantly improved outcomes for patients.

We are now enrolling in pivotal trials evaluating oral SM-88 as a potential treatment for patients with second- and third-line pancreatic cancer. We are also enrolling patients in a Phase II study evaluating SM-88 in high-risk sarcomas. To date, SM-88 is one of the rare investigational compounds that has demonstrated confirmed responses across 15 different tumor types.For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.
Ticker:
TYME
Exchange:
NASDAQ
Company Type:
Not Provided
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
SM-88 (racemetyrosine)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
three cancer metabolism-based compounds one which has confirmed clinical responses across 15 tumors
Speaker
photo
Chief Operating Officer
TYME Technologies Inc